Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Stargardt disease is an inherited juvenile macular degeneration that causes vision loss. The signs and symptoms of the disease typically appear in late childhood or early adulthood and worsen with time. The most common cause of the disease is mutations in the ABCA4 gene. People suffering from stargardt disease might notice grey or black color in the middle of eye, or eyes may be more sensitive to bright light. Others may even have symptoms of color blindness. The prevalence for the disease is low, reported at around 1 in 8,000-10,000 people globally, as stated by National Eye Institute in April 2015. Hence, the disease falls into rare disease category. Till date, there is no treatment available, though there are multiple therapies in pipeline.

The Global Stargardt Disease Therapeutics Market is estimated to be valued at US$ 213.5 million in 2023 and is expected to exhibit a CAGR of 31.7% during the forecast period (2023 - 2028).

Figure 1.Global Stargardt Disease Therapeutics Market Share (%) in Terms of Value, By Drug Type 2023

Stargardt Disease Therapeutics  | Coherent Market Insights

Robust pipeline for stargardt disease therapeutics is expected to drive the market growth during the forecast period.

Approval of some therapies that are currently in pipeline is expected to drive the Global Stargardt Disease Therapeutics Market growth over the forecast period. For instance, in November 2017, Nightstar Therapeutics, a subsidiary of Biogen Inc., expanded its pipeline with gene therapy program for Stargardt Disease treatment. Moreover, Biogen Inc. acquired Nightstar Therapeutics in March 2019, in order to establish clinical pipeline of gene therapy candidate for ophthalmology.

request-sample

Stargardt Disease Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2023: US$ 213.5 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 31.7% 2028 Value Projection: US$$ 1,701.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Emixustat, LBS-008
  • By Age Group: Children (Below17 Years), Adult (Above 17 Years)
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc, Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., F. Hoffmann-La Roche AG

Growth Drivers:
  • Robust pipeline for stargardt disease therapeutics
Restraints & Challenges:
  • Availability of alternatives to restore vision in patients with stargardt disease 

Figure 2.Global Stargardt Disease Therapeutics Market Share (%), by Distribution Channel, 2023

Stargardt Disease Therapeutics  | Coherent Market Insights

Key players focusing on strategic agreements for stargardt disease therapeutics   are expected to drive the market growth during the forecast period

Market players are focusing on various inorganic growth strategies such as agreements and acquisitions to accelerate the development of treatment for stargardt disease which is expected to boost the growth of the global stargardt disease therapeutics market over the forecast period. For instance, On January 11, 2021, Aker BioMarine, a fishing and biotech company, entered into an agreement with Dr. Michael Davidson, a biotech entrepreneur, to develop pharmaceutical therapies for diseases associated with brain and eye such as Alzheimer’s Disease, dry age-related macular degeneration, and Stargardt’s juvenile blindness, by using LYSOVETA, a process established by the biotech company, Aker BioMarine for production of lysophosphatidylcholine (LPC)-bound EPA (eicosapentaenoic acid)/DHA (docosahexaenoic acid) from krill

Global Stargardt Disease Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it as a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in more than 132 million infected individuals worldwide as of April 7, 2021.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to the transportation of drugs and devices from one place to another.

Furthermore, players operating in the global stargardt disease therapeutics market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials for manufacturing drug formulations due to irregularities in transportation facility. Moreover, distributors of products are experiencing irregular demand for products from the retailers due to increasing patient population suffering from COVID-19 and other life threatening disorders.

 Global Stargardt Disease Therapeutics Market: Restraint

The major factors that hinder growth of the Global Stargardt Disease Therapeutics Market include availability of alternatives to restore vision in patients with stargardt disease

Key Players

Major players operating in the Global Stargardt Disease Therapeutics Market are Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc, Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., F. Hoffmann-La Roche AG

Stargardt disease also called Stargardt's macular dystrophy (SMD) that affects approximately one in 10,000 people and described as central vision loss early in life. Stargardt Disease is most commonly caused by mutations in the ABCA4 gene located on chromosome 1 and is inherited in an autosomal recessive manner. This disorder affects the specialized light-sensitive tissue present in the retina. This type of macular degeneration affects the center of the retina which is known as macula which adds sharpness to the central vision. The affected individuals also show the symptoms of color blindness. The signs and symptoms appear in late childhood which is responsible for disease progression.

Market Dynamics

The increasing prevalence of stargardt disease is expected to drive the market growth over the forecast period. For instance, according to the article published in the Association for Research in Vision and Ophthalmology journal, the worldwide prevalence of stargardt disease is estimated to be in between 1 in 8,000 to 10,000 individuals.

Furthermore, key players operating in the Global Stargardt Disease Therapeutics Market are focusing on adoption of growth strategies are expected to drive the market growth during the forecast period.  For instance, in July 2017, Ophthotech Corporation, a clinical stage company, is adopting a new strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for which there are limited or no treatment options available. Ophthotech’s orphan ophthalmic disease strategy will be led by a randomized, controlled clinical trial assessing the efficacy and safety of Zimura (avacincaptad pegol), the company’s C5 complement inhibitor, for Stargardt disease.

Key features of the study:

  • This report provides in-depth analysis of the Global Stargardt Disease Therapeutics Market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2023–2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Global Stargardt Disease Therapeutics Market  based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
  • Key companies covered as a part of this study include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc, Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., F. Hoffmann-La Roche AG.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The Global Stargardt Disease Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Stargardt Disease Therapeutics Market .

Detailed Segmentation:

  • Global Stargardt Disease Therapeutics Market , By Drug Type:
    • Emixustat
    • LBS-008
  • Global Stargardt Disease Therapeutics Market , By Age Group:
    • Children (Below17 Years)
    • Adult (Above 17 Years)
  • Global Stargardt Disease Therapeutics Market , By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Stargardt Disease Therapeutics Market , By Region:
    • North America
      • By Drug Type
        • Emixustat
        • LBS-008
      • By Age Group
        • Children (Below17 Years)
        • Adult (Above 17 Years)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Type
        • Emixustat
        • LBS-008
      • By Age Group
        • Children (Below17 Years)
        • Adult (Above 17 Years)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type
        • Emixustat
        • LBS-008
      • By Age Group
        • Children (Below17 Years)
        • Adult (Above 17 Years)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Emixustat
        • LBS-008
      • By Age Group
        • Children (Below17 Years)
        • Adult (Above 17 Years)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type
        • Emixustat
        • LBS-008
      • By Age Group
        • Children (Below17 Years)
        • Adult (Above 17 Years)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Emixustat
        • LBS-008
      • By Age Group
        • Children (Below17 Years)
        • Adult (Above 17 Years)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Kubota Pharmaceutical Holdings Co., Ltd.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Stargazer Pharmaceuticals Inc.
    • Iveric Bio, Inc.
    • Sanofi S.A.
    • Alkeus Pharmaceuticals Inc.
    • Astellas Pharma Inc.
    • CHABiotech CO., Ltd
    • ReVision Therapeutics, Inc.
    • Lin BioScience, Inc.
    • Biogen Inc.
    • Hoffmann-La Roche AG

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Type
      • Market Snapshot, By Age Group
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Diagnosis of Stargardt Disease
    • Treatment of Stargardt Disease
    • Regulatory Scenario
    • Key Developments
    • Recent Approvals / Launches
    • Merger, Acquisitions, and Agreement
    • PEST Analysis
    • Epidemiology
  4. Global Stargardt Disease Therapeutics Market  – Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Impact on Overall the Healthcare Sector
    • COVID-19 Epidemiology
    • Supply and Demand Analysis
    • COVID-19 Impact on Clinical Trials and Drug Development
    • Initiatives Taken to Conduct Ongoing Clinical Trials
  5. Global Stargardt Disease Therapeutics Market , By Drug Type, 2023 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2028 (%)
      • Y-o-Y Growth Analysis, 2024 – 2028
      • Segment Trends
    • Emixustat
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2023–2028, (US$ Mn)
    • LBS-008
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2023–2028, (US$ Mn)
  6. Global Stargardt Disease Therapeutics Market , By Age Group, 2023 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2028 (%)
      • Y-o-Y Growth Analysis, 2024 – 2028
      • Segment Trends
    • Children (Below17 Years)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2023–2028, (US$ Mn)
    • Adult (Above 17 Years)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2023–2028, (US$ Mn)
  7. Global Stargardt Disease Therapeutics Market , By Distribution Channel, 2023 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2028 (%)
      • Y-o-Y Growth Analysis, 2024 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2023–2028, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2023–2028, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2023–2028, (US$ Mn)
  8. Global Stargardt Disease Therapeutics Market , By Region, , 2023 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2023 and 2028 (%)
      • Y-o-Y Growth Analysis, 2024 – 2028
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Country, 2023–2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Country, 2023–2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Country, 2023–2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Country, 2023–2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Country, 2023–2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023–2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth,  By Country, 2023–2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Kubota Pharmaceutical Holdings Co., Ltd.*
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Stargazer Pharmaceuticals Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Iveric Bio, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Sanofi S.A.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Alkeus Pharmaceuticals Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Astellas Pharma Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • CHABiotech CO., Ltd
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • ReVision Therapeutics, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Lin BioScience, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Biogen Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
      • Hoffmann-La Roche AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Strategies
  10. Section
    • Research Methodology
    • About us

*Browse 35 market data tables and 30 figures on "Global Stargardt Disease Therapeutics Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The Global Stargardt Disease Therapeutics Market size is estimated to be valued at US$ 213.5 million in 2023 and is expected to exhibit a CAGR of 31.7 % between 2023 and 2028.
Robust pipeline for stargardt disease therapeutics is expected to drive the market growth during the forecast period.
Emixustat drug type segment is expected to hold a major market share during the forecast period.
The major factors hampering growth of the market include availability of alternatives to restore vision in patients with stargardt disease
Major players operating in the market are Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc, Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., F. Hoffmann-La Roche AG
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.